Neovacs S.A. (EPA:ALNEV)

France · Delayed Price · Currency is EUR

0.0799

-0.0065 (-7.52%)

Nov 10, 2026, 3:03 PM CET

Market Cap	12.71K -32.4%
Revenue (ttm)	810.20K +188.7%
Net Income	-4.09M
EPS	n/a
Shares Out	159.06K
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	433,242
Open	0.0815
Previous Close	0.0864
Day's Range	0.0749 - 0.0863
52-Week Range	0.0749 - 372.0000
Beta	-1,328.96
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 4, 2026

About Neovacs

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company’s product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies. IFNα Kinoid, an anti-interferon alpha vaccine which completed Phase I / IIa and IIb clinical trial for the treatment of lupus erythematosus; and Phase II... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1993

Employees 20

Stock Exchange Euronext Paris

Ticker Symbol ALNEV

Full Company Profile

Financial Performance

In 2025, Neovacs's revenue was 401,006, a decrease of -7.59% compared to the previous year's 433,937. Losses were -4.90 million, -85.12% less than in 2024.

Financial Statements